Cargando…

Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis

OBJECTIVE: This study was designed to explore the predictive value of plasma phenylalanine (Phe) and gut microbiota-derived metabolite phenylacetylglutamine (PAGln) in coronary in-stent restenosis (ISR). METHODS: Patients with coronary ISR, in-stent hyperplasia (ISH), and in-stent patency (ISP) were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Yuan, Yang, Yixing, Fang, Chen, Liu, Xinming, Dong, Ying, Xu, Li, Chen, Mulei, Zuo, Kun, Wang, Lefeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468445/ https://www.ncbi.nlm.nih.gov/pubmed/36110409 http://dx.doi.org/10.3389/fcvm.2022.944155

Ejemplares similares

Dysbiosis of Gut Microbiota and Metabolite Phenylacetylglutamine in Coronary Artery Disease Patients With Stent Stenosis
por: Fang, Chen, et al.
Publicado: (2022)

Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure
por: Zhang, Zhendong, et al.
Publicado: (2023)

Phenylacetylglutamine, a Novel Biomarker in Acute Ischemic Stroke
por: Yu, Fang, et al.
Publicado: (2021)

Heavy Coronary Calcium Mimicking In-Stent Restenosis
por: Park, Jeong-Hwan, et al.
Publicado: (2011)

Gut-Derived Metabolite Phenylacetylglutamine and White Matter Hyperintensities in Patients With Acute Ischemic Stroke
por: Yu, Fang, et al.
Publicado: (2021)

Intravascular imaging in coronary stent restenosis: Prevention, characterization, and management
por: Abouelnour, Amr, et al.
Publicado: (2022)

Predictors of restenosis following percutaneous coronary stent implantation: The role of trimetazidine therapy
por: Csató, Gábor, et al.
Publicado: (2022)

Coronary Angioscopy Findings before and after Excimer Laser Coronary Angioplasty for Bare-Metal Stent In-Stent Restenosis
por: Masuda, Shinichiro, et al.
Publicado: (2019)

Coronary stent restenosis and the association with allergy to metal content of 316L stainless steel
por: D, Slodownik, et al.
Publicado: (2018)

Risk investigation of in-stent restenosis after initial implantation of intracoronary drug-eluting stent in patients with coronary heart disease
por: Xi, Hongfei, et al.
Publicado: (2023)

The Predictive Value of the Perivascular Adipose Tissue CT Fat Attenuation Index for Coronary In-stent Restenosis
por: Qin, Bin, et al.
Publicado: (2022)

Urine Phenylacetylglutamine Determination in Patients with Hyperphenylalaninemia
por: Andrade, Fernando, et al.
Publicado: (2021)

Serum glycated albumin is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents: An observational study
por: Lin, Xiao Long, et al.
Publicado: (2022)

Hypersensitivity and in-stent restenosis in coronary stent materials
por: Hu, Wansong, et al.
Publicado: (2022)

Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting for Treating In-Stent Restenosis in Unprotected-Left Main: LM-DRAGON-Registry
por: Wańha, Wojciech, et al.
Publicado: (2022)

Unusually aggressive immature neo-intimal hyperplasia causing in-stent restenosis
por: Keir, McCutcheon, et al.
Publicado: (2017)

Plasma Proteome Profiling of Patients With In-stent Restenosis by Tandem Mass Tag-Based Quantitative Proteomics Approach
por: Hou, Jingyuan, et al.
Publicado: (2022)

The Effects of Moderate Alcohol Consumption on Circulating Metabolites and Gut Microbiota in Patients With Coronary Artery Disease
por: Zhao, Xinyue, et al.
Publicado: (2021)

The Early Predictive Value of Circulating Monocytes and Eosinophils in Coronary DES Restenosis
por: Li, Shumei, et al.
Publicado: (2022)

Prevalence, predictors, and management for balloon uncrossable or undilatable lesions in patients undergoing percutaneous coronary intervention with in-stent restenosis chronic total occlusion
por: Wang, Yong, et al.
Publicado: (2023)

Efficacy of intramuscular methyl prednisolone in preventing restenosis after coronary artery stenting with bare-metal stainless steel stent: a double-blind, randomised, controlled clinical trial
por: Namdari, M, et al.
Publicado: (2011)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

In stent restenosis after percutaneous coronary intervention
por: Eyüboğlu, Mehmet
Publicado: (2016)

Nomograms Based on Non-High-Density Lipoprotein to Predict Outcomes in Patients with Prior Coronary Artery Bypass Grafting with Acute Coronary Syndrome: A Single-Center Retrospective Study
por: Li, Chuang, et al.
Publicado: (2023)

Investigation Into the Risk Factors Related to In-stent Restenosis in Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Within 2 Years After the First Drug-Eluting Stent Implantation
por: Yi, Ming, et al.
Publicado: (2022)

Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure
por: Zong, Xiao, et al.
Publicado: (2022)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Diagnostic value of intraluminal stent enhancement in estimating coronary in-stent restenosis
por: Nogourani, Mehdi Karami, et al.
Publicado: (2020)

Coated stents to prevent restenosis in coronary heart disease
por: Gorenoi, Vitali, et al.
Publicado: (2005)

Drug- and Gene-eluting Stents for Preventing Coronary Restenosis
por: Lekshmi, Kamali Manickavasagam, et al.
Publicado: (2017)

Treatment of coronary in-stent restenosis: a systematic review
por: Pleva, Leos, et al.
Publicado: (2018)

Diagnosis and management challenges of in-stent restenosis in coronary arteries
por: Alraies, M Chadi, et al.
Publicado: (2017)

Comparison of new-generation drug-eluting stents versus drug-coated balloon for in-stent restenosis: a meta-analysis of randomised controlled trials
por: Cai, Jin-Zan, et al.
Publicado: (2018)

Combination treatment with asiaticoside and rapamycin: A new hope for in-stent restenosis
por: GUO, TIAN, et al.
Publicado: (2013)

Nanotechnology for the treatment of coronary in stent restenosis: a clinical perspective
por: McDowell, Garry, et al.
Publicado: (2011)

Differential Expression of miRNA-223 in Coronary In-Stent Restenosis
por: Ganjali, Shiva, et al.
Publicado: (2022)

Impact of anemia on in-stent restenosis after percutaneous coronary intervention
por: Hu, Huilin, et al.
Publicado: (2021)

Phenylacetylglutamine as a novel biomarker of type 2 diabetes with distal symmetric polyneuropathy by metabolomics
por: Xu, J., et al.
Publicado: (2022)

Usefulness of Platelet Distribution Width and Fibrinogen in Predicting In-stent Restenosis With Stable Angina and Type 2 Patients With Diabetes Mellitus
por: Chai, Dayang, et al.
Publicado: (2022)

Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events
por: Wang, Xiaofeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4n6453eseni76of6dhqm1t3ovt